StockNews.AI
PRTA
StockNews.AI
187 days

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

1. Prothena will announce Q4 and 2024 results on February 20, 2025. 2. The company focuses on protein dysregulation and investigational therapeutics. 3. Pipeline includes treatments for neurodegenerative and rare amyloid diseases. 4. A conference call will follow the results announcement for detailed insights.

Earnings
+2.02%Current Return
VS
0%S&P 500
$13.8902/13 04:35 PM EDTEvent Start
$14.1702/14 10:59 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings report may not surpass existing market expectations, leading to a stable price. Prior earnings releases have shown minimal immediate effect on PRTA price.

How important is it?

Earnings reports are critical for financial forecasting, impacting investor sentiment. However, the established pipeline could stabilize PRTA's performance despite earnings variability.

Why Short Term?

The earnings report's influence will primarily be felt in the short-term. Immediate market reactions are typical around earnings announcements.

Related Companies

ALNYBIIBREGN
DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. To access the call via dial-in, please dial +1 (800) 715-9871 (U.S. and Canada toll free) or +1 (646) 307-1963 (international) five minutes prior to the start time and refer to conference ID number 9788564. A replay of the call will be available until February 22, 2024, via dial-in at +1 (800) 770-2030 (U.S. and Canada toll free) or +1 (609) 800-9909 (international), Conference ID Number 9788564. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.

Related News